Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00757757 · ClinicalTrials.gov registry record · Phase 1

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

A Phase 1 study, sponsored by Novartis Pharmaceuticals.

Terminated
Registry status
Phase 1
Development phase
3
Enrollment target

NCT00757757 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00757757, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.

TERMINATED
Registry status
Phase 1
Development phase
3 participants
Enrollment target

Study Summary

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

Interventions

  • DRUG MCS110

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2008-09
Est. Completion 2009-08
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

What the Registry Record Tells You About NCT00757757

The ClinicalTrials.gov registry entry for NCT00757757 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which MCS110 is the first listed.

NCT00757757 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00757757 about?

NCT00757757 is a clinical study titled "A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases". This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

What is the current status of trial NCT00757757?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-09. Estimated completion is 2009-08.

What interventions are being tested in trial NCT00757757?

The interventions under investigation include: MCS110 (DRUG).

Who is sponsoring clinical trial NCT00757757?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.